Ferinject® (ferric carboxymaltose) Dosing and Administration Summary! Ferinject® does not require the Ganzoni formula to determine required dose Ferinject® only requires patient’s current weight and current haemoglobin (Hb) level to calculate the required dose of iron* <10 1500 mg 2000 mg 210 1000 mg 1500 mg * For overweight patients a normal body weight / blood volume relationship should be assumed when determining the iron requirement. ‘A cumulative iron dose of 500 mg should not be exceeded for patients wth a body weight <35 kg For patients with an Hb 14g/¢L, an initial dose of 500 mg should be given and ion parameters checked prior to repeat dosing, Ferinject® should only be administered wihen staff trained to evaluate and manage anaphylactic reactions is immediately available in an environment vahere full resuscitation facilities can be assured, The patient should be observed for adverse effects for atleast 30 minutes following each Ferinject injection. ® A maximum single dose of 20 mg/kg body weight up to 1000 mg of iron can be administered by intravenous drip infusion @ A maximum single dose of 15 mg/kg body weight up to 1000 mg of iron can be administered by intravenous injection ® Do not administer 1000 mg of iron more than once per week Ferinject® can be administered up to 1000 mg as an IV infusion or IV injection 100 to 200 mg 50 mi : 2200 to 500mg 100 mi 6 minutes 2500 to 1000 mg 250 ml 15 minutes Forstabilty reasons, dilution to concentrations less than 2 mg iron / ml are not permissible. ‘Maximum amount of sterile 0.9% m/V sodium chloride solution. Administer undiluted Ferinject® by the intravenous injection route, 0-200 mg : >200-s500 mg 100 mg/min >500 mg-s1000 mg 15 minutes No test dose requirement Prescribing information= Vifor Pharma )ferinject eee Ned Dancer) Dec uC cag Corn eee pom once a ene ee Teta Pree era] roe ren eee ae eke er nr ee nod arene reer ete ae | eno mute nl ee en Peet a ee et ene | eee ee rd eS enue Teen ee ree nae er mney eee etre ein to 20mgikg bodyweight. erect must be dtd in 09% mV pect eet Pe Cremer rst) omens rer ney peeren cei rene er re ae eet perme nT ee ec cio The sk is enhanced for patients wth known alge, a histny Cees er Corea rater acceded ‘ony be administered in the presence of staf trained to manage Caen ean erect es Renee ne mee are Pere ee ee on Pere nnn ny ee ee eee eens ee eet en erage Peer nes eeer er ron ee ee nd en ee ter en eer) pees lapianes pemyaaty ycaerss “eine amare ee eee rs Pon ee ay Serene) be exercised 10 void paravenaus leakage or eet nia ene nn ere ae) ee ae ee) Se eM ea re es Se eae ety ree ne Pee ee te pene aren een ene ene oem ere Carrer Presa er ane ena Pere ar Omen Mra teat to) ee ene a Senet rere cc eed Pree er eee ror See ree Seer Pa ee ed cee ee ea reported, epting fom and irermation can be found at rn arrest Ree ern Peer eta! ere Date of preparation: November 2013 Per ie crernnnien